NTU's Groundbreaking Urine Test Ushers in New Era for Dengue Management in Singapore
Singapore's Nanyang Technological University (NTU) has once again positioned itself at the forefront of biomedical innovation with a novel urine-based test that not only detects dengue virus infection but also predicts the likelihood of severe outcomes. This development from NTU's Lee Kong Chian School of Medicine (LKCMedicine) addresses a critical gap in tropical disease diagnostics, where early identification of high-risk patients can dramatically alter treatment strategies and reduce hospitalization rates.
Dengue, transmitted by Aedes mosquitoes, remains a persistent public health challenge in Singapore despite significant declines in cases. In 2025, the National Environment Agency (NEA) reported 4,036 cases—a 70% drop from 13,651 in 2024—thanks to initiatives like Project Wolbachia. However, early 2026 data shows ongoing clusters, with 25 cases in the week ending April 4 and two active clusters as of April 10. Globally, dengue affects millions annually, with severe cases leading to plasma leakage, organ failure, and death in about 1 in 20 hospitalized patients. NTU's research promises to transform how clinicians triage patients, potentially allowing low-risk individuals to recover at home.
The breakthrough builds on NTU's prior work identifying blood biomarkers like suppression of tumorigenicity 2 (sST2) and soluble urokinase plasminogen activator receptor (suPAR) in 2023. Now, shifting to urine—a non-invasive, patient-friendly sample—the team has validated its prognostic power.
The Science: Key Proteins in Urine Signal Dengue Severity
The test targets three key molecules in urine: the dengue non-structural protein 1 (NS1) antigen for confirming infection, and two neutrophil-derived biomarkers—neutrophil gelatinase-associated lipocalin (NGAL) and suPAR—for severity prediction. NS1, shed by the dengue virus (DENV), appears early in infection (days 1-4), enabling detection before symptoms peak.
NGAL, released by activated neutrophils (white blood cells), indicates kidney stress and inflammation, common in severe dengue. suPAR, a marker of immune activation and endothelial damage, reflects vascular leakage—a hallmark of dengue hemorrhagic fever (DHF). In the study, these proteins were significantly elevated in severe cases compared to mild ones.
Step-by-step process:
- Sample collection: Patients provide a simple urine sample at clinic visit.
- Detection: Lateral flow assay (like pregnancy tests) identifies NS1.
- Severity assessment: Quantitative measurement of NGAL and suPAR via immunoassay.
- Risk stratification: High levels (e.g., NGAL >50 ng/mL) flag hospitalization need.
This approach outperforms symptom-based screening (abdominal pain, vomiting), which has only 6-18% accuracy.
Study Design and Impressive Results from NTU's Cohort
Led by Assistant Professor Andrew Teo from LKCMedicine and Dr. Chia Po Ying, the prospective study enrolled 181 adults with lab-confirmed dengue at Singapore's National Centre for Infectious Diseases (NCID) between 2021-2023. Urine samples were collected during the febrile phase (days 1-3 post-symptom onset), analyzed for biomarkers, and correlated with clinical outcomes.
Results:
| Biomarker | AUROC for Severe Dengue | Odds Ratio (High vs Low) |
|---|---|---|
| NGAL | 0.89 | 12.5 |
| suPAR | 0.82 | 8.2 |
| NS1 + NGAL + suPAR | 0.92 | 15.3 |
Severe dengue defined by WHO criteria (plasma leakage, shock, organ impairment). The model predicted hospitalization need with 85% sensitivity and 80% specificity, 3-4 times better than symptoms alone. No overlap with other fevers like Zika or chikungunya.
The paper, published January 9, 2026, in Open Forum Infectious Diseases, underscores urine's stability for point-of-care testing.Read the full study.
Advantages: Non-Invasive, Rapid, and Cost-Effective
- Patient comfort: Urine vs blood draw, ideal for children/elderly.
- Speed: Results in minutes, unlike lab NS1 tests (hours).
- Accessibility: Home kits possible, reducing clinic overload.
- Equity: Useful in rural/endemic areas without labs.
- Cost savings: Early triage cuts unnecessary admissions (SG spends millions yearly on dengue).
Dr. Teo notes: "This empowers patients and eases healthcare burden."
Photo by National Cancer Institute on Unsplash
Public Health Impact in Singapore and Beyond
Singapore's proactive vector control (Wolbachia mosquitoes covering 80% urban areas by 2026) has curbed cases, but vigilance needed amid climate change boosting Aedes habitats. NTU's test complements this, enabling targeted interventions.
Globally, dengue hits 400 million yearly (WHO), mostly tropics. Validation in Sri Lanka underway. In SG, NEA reports 2 clusters April 2026; test could alert GPs early.Straits Times coverage.
Reduces antibiotic overuse (common in misdiagnosed fevers) and hospital strain.
NTU's Biomedical Research Excellence and Interdisciplinary Collaboration
NTU, ranked top young university globally (QS), invests heavily in health sciences. LKCMedicine partners NHG/NCID; School of Biological Sciences provides proteomics expertise. Andrew Teo, Dean's Postdoc Fellow, specializes in dengue immunology.
This aligns with Singapore's Research, Innovation, Enterprise 2025 plan, fostering biotech hubs like Biopolis. NTU's labs feature advanced mass spectrometry for biomarker discovery.
Towards Home Dengue Test Kits: Next Steps at NTU
Team targets all-in-one lateral flow kit (NS1 + biomarkers) within 5 years, like COVID tests. Validation trials planned; regulatory approval via HSA. Potential export to ASEAN dengue hotspots.
Challenges: Standardizing cut-offs, multi-serotype accuracy (DENV1-4).
Career Opportunities in Dengue Research at Singapore Universities
NTU seeks postdocs, research assistants in infectious diseases. Skills: ELISA, proteomics, clinical trials. LKCMedicine offers PhDs; salaries S$5k-8k/month.Explore NTU research jobs.
- Biomedical engineers for kit development.
- Immunologists for validation studies.
- Data scientists for AI-enhanced prediction.
Rate NTU profs on Rate My Professor for insights.
Photo by National Cancer Institute on Unsplash
NTU's Broader Contributions to Tropical Medicine
NTU leads in Wolbachia modeling, COVID-dengue dual tests. Collaborations with A*STAR, NCID drive translation. Impacts SG's '30x30' biotech goal: 30 companies, S$30B GDP by 2030.
Future Outlook: Transforming Global Dengue Care
As climate change expands Aedes range, NTU's test scales solutions. Integration with apps/telemedicine envisioned. Singapore universities like NTU exemplify higher ed's role in health security, inspiring careers in research.
For updates, follow NTU LKCMedicine.NTU press release.
